EP4061378A1 - A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent - Google Patents
A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solventInfo
- Publication number
- EP4061378A1 EP4061378A1 EP20890661.0A EP20890661A EP4061378A1 EP 4061378 A1 EP4061378 A1 EP 4061378A1 EP 20890661 A EP20890661 A EP 20890661A EP 4061378 A1 EP4061378 A1 EP 4061378A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- solid pharmaceutical
- composition according
- sodium
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title claims abstract description 33
- 239000007787 solid Substances 0.000 title claims abstract description 31
- 229960003834 dapagliflozin Drugs 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 239000002798 polar solvent Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 15
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- 229960004977 anhydrous lactose Drugs 0.000 claims description 9
- 229960000913 crospovidone Drugs 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 9
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 9
- 239000007884 disintegrant Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 229960001866 silicon dioxide Drugs 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229960001031 glucose Drugs 0.000 claims description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000000378 calcium silicate Substances 0.000 claims description 4
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 4
- 235000012241 calcium silicate Nutrition 0.000 claims description 4
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229940032147 starch Drugs 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 235000012222 talc Nutrition 0.000 claims description 4
- -1 dextrates Chemical compound 0.000 claims description 3
- 229960004592 isopropanol Drugs 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 claims description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 235000001465 calcium Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 239000008119 colloidal silica Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229940096516 dextrates Drugs 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims description 2
- 229960000878 docusate sodium Drugs 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000008203 oral pharmaceutical composition Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- GOADIQFWSVMMRJ-UPGAGZFNSA-N dapagliflozin propanediol monohydrate Chemical compound O.C[C@H](O)CO.C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl GOADIQFWSVMMRJ-UPGAGZFNSA-N 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 229940110266 farxiga Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
Definitions
- the present invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent and at least one pharmaceutically acceptable excipients. Further the present invention provides a method for the preparation of said composition.
- Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
- Type 1 and Type 2 There are two main types of diabetes; Type 1 and Type 2:
- Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
- Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
- Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2) indicated in the treatment of diabetes mellitus, in particular type 2 diabetes. It prevents reabsorption of at least 90% of the glucose in the kidney and facilitates elimination of the glucose through the urine.
- SGLT2 sodium-glucose cotransporter 2 inhibitor
- Dapagliflozin also known as (1S)-1 ,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl] phenyl]-D-glucitol, is represented by the structure of formula I.
- Dapagliflozin is an orally active SGLT2 inhibitor that is disclosed in US6515117 patent application.
- FARXIGA ® In the United States of America, it is available as immediate release tablets in the dose strengths of 5 mg and 10 mg under the brand name FARXIGA ® .
- the active ingredient in FARXIGA ® is a crystalline form of dapagliflozin propylene glycol hydrate.
- EP2508188 (A1) patent application discloses immediate release pharmaceutical formulation which includes a tablet or capsule formulation containing dapagliflozin propylene glycol hydrate for treatment of diabetes.
- the main object of the present invention is to provide a solid pharmaceutical composition comprising amorphous dapagliflozin with desired dissolution profiles.
- the other object of the present invention is to enhance excellent pharmacotechnical properties (i.e. flowability, compressibility and homogeneity).
- the other object of the present invention is to provide an easy and cost-effective process for the preparation of the said pharmaceutical composition.
- a solid pharmaceutical composition comprises amorphous dapagliflozin isolated from a polar solvent and at least one pharmaceutically acceptable excipients.
- the amount of amorphous dapagliflozin is between 1 0%-50.0% by weight of the total composition.
- the amount of amorphous dapagliflozin is between 1 0%-40.0% or 1 0%-30.0% or 1 0%-20.0% or 1 0%-10.0% or 1.0%-
- suitable polar solvent is selected from the group comprising acetone, acetonitrile, ethanol, methanol, n-propanol, iso-propanol, water or mixtures thereof.
- the polar solvent is acetone.
- the polar solvent is acetonitrile.
- the polar solvent is ethanol.
- the polar solvent is methanol.
- the polar solvent is n-propanol.
- the polar solvent is iso-propanol.
- the polar solvent is water.
- pharmaceutically acceptable excipients are selected from the group comprising fillers, disintegrants, lubricants, glidants or mixtures thereof.
- excipients and amounts has more importance to enhance excellent pharmacotechnical properties (i.e flowability, compressibility and homogeneity). Especially, used filler and its ratio use in the composition are very important.
- Suitable fillers are selected from group comprising microcrystalline cellulose, anhydrous lactose, mannitol, sorbitol, sucrose, inorganic salts, calcium salts, spray-dried lactose, calcium silicate, polysaccharides, dextrose, sodium chloride, dextrates, lactitol, sugar pellet, lactose monohydrate, starch, maltodextrin, dibasic calcium phosphate, sucrose-maltodextrin mixtures, xylitol, trehalose, heavy magnesium carbonate, isomalt, or mixtures thereof.
- the amount of fillers is between 10.0%-90.0% by weight of the total composition. According to this embodiment of the invention, the amount of fillers is between 20.0%-90.0% or 30.0%-90.0% or 40.0%-90.0% or 50.0%-90.0% or 60.0%-90.0% or 70.0%-90.0% or 80.0%-90.0% by weight of the total composition.
- filler is microcrystalline cellulose or anhydrous lactose or mixtures thereof.
- Suitable disintegrants are selected from the group comprising crospovidone, povidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, polyacrylate potassium, sodium alginate, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
- the amount of disintegrants is between 0.5%- 20.0% by weight of the total composition.
- the amount of disintegrants is between 0.5%- 15.0% or 0.5%-10.0% or 1 0%-8.0% or 1 0%-6.0% by weight of the total composition.
- disintegrant is crospovidone.
- Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
- the amount of lubricants is between 0.05%- 5.0% by weight of the total composition.
- lubricant is magnesium stearate.
- Suitable glidants are selected from the group comprising silicon dioxide, talc, aluminium silicate, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
- the amount of glidants is between 0.05%- 5.0% by weight of the total composition.
- glidant is silicon dioxide.
- the solid oral pharmaceutical composition is in the form of a tablet or a capsule.
- the solid oral pharmaceutical composition of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, dry granulation or wet granulation.
- the formulation when the composition is prepared with direct compression, the formulation has excellent pharmacotechnical properties (i.e flowability, compressibility and homogeneity) and desired dissolution rate.
- the solid oral pharmaceutical composition comprises;
- the solid pharmaceutical composition comprises;
- magnesium stearate - 0.05% - 5.0% by weight of magnesium stearate
- Example 1 The solid oral pharmaceutical composition
- Example 2 The solid oral pharmaceutical composition
- Example 3 A tablet comprising amorphous dapagliflozin isolated from polar solvent
- Example 4 A tablet comprising amorphous dapagliflozin isolated from polar solvent
- Process for preparing the solid oral pharmaceutical composition comprises the following steps: - Mixing amort dapagliflozin, microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide
- Example 5 A capsule comprising amorphous dapagliflozin isolated from polar solvent
- Process for preparing the solid oral pharmaceutical composition comprises the following steps:
- a product is considered very rapidly dissolving when 85 percent or more of the labeled amount of the drug substance dissolves within 15 minutes according to United States Pharmacopeia (USP).
- USP United States Pharmacopeia
- formulations 2 (Amorphous dapagliflozin isolated from apolar solvent) is still not dissolved completely in 15. minutes.
- Formulations 1 (Amorphous dapagliflozin isolated from polar solvent) is categorized as “very rapidly dissolving” according to USP since, %99.8 of said formulation are dissolved within 15 minutes.
- formulation 1 Amorphous dapagliflozin isolated from polar solvent
- formulation 2 Amorphous dapagliflozin isolated from polar solvent
- the measured dissolution profiles of the disclosed formulations clearly demonstrate the advantageous technical effect of the invention.
- the said apolar solvents of example 6 is selected from the group comprising benzene, carbon tetrachloride, cyclohexane, diethyl ether, heptane, hexane, methyl butyl ether, pentane, diisopropyl ether, toluene, tichloroethylene, xylene.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent and at least one pharmaceutically acceptable excipients. Further the present invention provides a method for the preparation of said composition.
Description
A SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS DAPAGLIFLOZIN ISOLATED FROM A POLAR SOLVENT
Field of The Invention
The present invention relates to a solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent and at least one pharmaceutically acceptable excipients. Further the present invention provides a method for the preparation of said composition.
Background of The Invention
Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors. There are two main types of diabetes; Type 1 and Type 2:
Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
In Type 2 diabetes, the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2) indicated in the treatment of diabetes mellitus, in particular type 2 diabetes. It prevents reabsorption of at least 90% of the glucose in the kidney and facilitates elimination of the glucose through the urine.
Dapagliflozin, also known as (1S)-1 ,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl] phenyl]-D-glucitol, is represented by the structure of formula I.
Formula I
Dapagliflozin is an orally active SGLT2 inhibitor that is disclosed in US6515117 patent application.
In the United States of America, it is available as immediate release tablets in the dose strengths of 5 mg and 10 mg under the brand name FARXIGA®. The active ingredient in FARXIGA® is a crystalline form of dapagliflozin propylene glycol hydrate.
EP2508188 (A1) patent application discloses immediate release pharmaceutical formulation which includes a tablet or capsule formulation containing dapagliflozin propylene glycol hydrate for treatment of diabetes.
Therefore, there is still need for new approaches in order to develop dapagliflozin formulations produced in a pharmaceutical composition.
Detailed Description of The Invention
The main object of the present invention is to provide a solid pharmaceutical composition comprising amorphous dapagliflozin with desired dissolution profiles.
The other object of the present invention is to enhance excellent pharmacotechnical properties (i.e. flowability, compressibility and homogeneity).
The other object of the present invention is to provide an easy and cost-effective process for the preparation of the said pharmaceutical composition.
Surprisingly, it has been found that a solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent provides desired dissolution profile (see example 6).
According to this embodiment of the present invention, a solid pharmaceutical composition comprises amorphous dapagliflozin isolated from a polar solvent and at least one pharmaceutically acceptable excipients.
According to this embodiment of the present invention, the amount of amorphous dapagliflozin is between 1 0%-50.0% by weight of the total composition.
According to this embodiment of the present invention, the amount of amorphous dapagliflozin is between 1 0%-40.0% or 1 0%-30.0% or 1 0%-20.0% or 1 0%-10.0% or 1.0%-
8.0% or 1 0%-6.0% by weight of the total composition.
According to this embodiment of the present invention, suitable polar solvent is selected from the group comprising acetone, acetonitrile, ethanol, methanol, n-propanol, iso-propanol, water or mixtures thereof.
According to this embodiment of the present invention, the polar solvent is acetone.
According to this embodiment of the present invention, the polar solvent is acetonitrile.
According to this embodiment of the present invention, the polar solvent is ethanol.
According to this embodiment of the present invention, the polar solvent is methanol.
According to this embodiment of the present invention, the polar solvent is n-propanol.
According to this embodiment of the present invention, the polar solvent is iso-propanol.
According to this embodiment of the present invention, the polar solvent is water.
According to this embodiment of the present invention, pharmaceutically acceptable excipients are selected from the group comprising fillers, disintegrants, lubricants, glidants or mixtures thereof.
The selection of excipients and amounts has more importance to enhance excellent pharmacotechnical properties (i.e flowability, compressibility and homogeneity). Especially, used filler and its ratio use in the composition are very important.
Suitable fillers are selected from group comprising microcrystalline cellulose, anhydrous lactose, mannitol, sorbitol, sucrose, inorganic salts, calcium salts, spray-dried lactose, calcium silicate, polysaccharides, dextrose, sodium chloride, dextrates, lactitol, sugar pellet, lactose monohydrate, starch, maltodextrin, dibasic calcium phosphate, sucrose-maltodextrin mixtures, xylitol, trehalose, heavy magnesium carbonate, isomalt, or mixtures thereof.
According to this embodiment of the invention, the amount of fillers is between 10.0%-90.0% by weight of the total composition.
According to this embodiment of the invention, the amount of fillers is between 20.0%-90.0% or 30.0%-90.0% or 40.0%-90.0% or 50.0%-90.0% or 60.0%-90.0% or 70.0%-90.0% or 80.0%-90.0% by weight of the total composition.
According to this embodiment of the invention, filler is microcrystalline cellulose or anhydrous lactose or mixtures thereof.
Suitable disintegrants are selected from the group comprising crospovidone, povidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, polyacrylate potassium, sodium alginate, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
According to this embodiment of the invention, the amount of disintegrants is between 0.5%- 20.0% by weight of the total composition.
According to this embodiment of the invention, the amount of disintegrants is between 0.5%- 15.0% or 0.5%-10.0% or 1 0%-8.0% or 1 0%-6.0% by weight of the total composition.
According to this embodiment of the invention, disintegrant is crospovidone.
Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
According to this embodiment of the invention, the amount of lubricants is between 0.05%- 5.0% by weight of the total composition.
According to this embodiment of the invention, lubricant is magnesium stearate.
Suitable glidants are selected from the group comprising silicon dioxide, talc, aluminium silicate, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
According to this embodiment of the invention, the amount of glidants is between 0.05%- 5.0% by weight of the total composition.
According to this embodiment of the invention, glidant is silicon dioxide.
According to this embodiment of the invention, the solid oral pharmaceutical composition is in the form of a tablet or a capsule.
The solid oral pharmaceutical composition of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, dry granulation or wet granulation.
According to one embodiment of the present invention, it has been found that when the composition is prepared with direct compression, the formulation has excellent pharmacotechnical properties (i.e flowability, compressibility and homogeneity) and desired dissolution rate.
According to one embodiment of the present invention, the solid oral pharmaceutical composition comprises;
- Amorphous dapagliflozin isolated from polar solvent
- Microcrystalline cellulose
- Anhydrous lactose
- Crospovidone
- Magnesium stearate
- Silicon dioxide
According to one embodiment of the present invention, the solid pharmaceutical composition comprises;
- 1 .0%- 50.0% by weight of amorphous dapagliflozin isolated from polar solvent
- 10.0% - 90.0% by weight of microcrystalline cellulose
- 5.0% - 30.0% by weight of anhydrous lactose
- 0.5% - 20.0% by weight of crospovidone
- 0.05% - 5.0% by weight of magnesium stearate
- 0.05% - 5.0% by weight of silicon dioxide in the total composition.
Example 1 : The solid oral pharmaceutical composition
Example 2: The solid oral pharmaceutical composition
Example 3: A tablet comprising amorphous dapagliflozin isolated from polar solvent
Example 4: A tablet comprising amorphous dapagliflozin isolated from polar solvent
Process for example 3 or 4:
Process for preparing the solid oral pharmaceutical composition comprises the following steps: - Mixing amort dapagliflozin, microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide
- Adding magnesium stearate and then mixing,
- Compressing the total mixture into tablets.
Example 5: A capsule comprising amorphous dapagliflozin isolated from polar solvent
Process for example 5:
Process for preparing the solid oral pharmaceutical composition comprises the following steps:
- Mixing amort dapagliflozin, microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide
- Adding magnesium stearate and then mixing,
- Filling the mixture into capsules.
Example 6: Dissolution study
Dissolution parameters - Using USP apparatus II
Rotation speed 50 rpm/min Temperature 37 °C ± 0.5 °C Dissolution medium 900 ml_, pH 4.5 acetate buffer
A product is considered very rapidly dissolving when 85 percent or more of the labeled amount of the drug substance dissolves within 15 minutes according to United States Pharmacopeia (USP).
According to the above information, formulations 2 (Amorphous dapagliflozin isolated from apolar solvent) is still not dissolved completely in 15. minutes. On the other hand, Formulations 1 (Amorphous dapagliflozin isolated from polar solvent) is categorized as “very rapidly dissolving” according to USP since, %99.8 of said formulation are dissolved within 15 minutes.
The comparison between the tests results of said two formulations are carried out on the data obtained in the stability period of said formulations (10th minute). As shown, the dissolution data of Formulation 1 which is amorphous dapagliflozin isolated from polar solvent proposes the desired dissolution profile. On the other hand, it is clear that the dissolution data of formulation 2 is significantly lower than the dissolution data of the formulation 1.
Consequently, this study shows the advantageous effect of selecting formulation 1 (Amorphous dapagliflozin isolated from polar solvent) to enhance the solubility of said dapagliflozin formulation compared to formulation 2. the measured dissolution profiles of the disclosed formulations clearly demonstrate the advantageous technical effect of the invention.
The said apolar solvents of example 6 is selected from the group comprising benzene, carbon tetrachloride, cyclohexane, diethyl ether, heptane, hexane, methyl butyl ether, pentane, diisopropyl ether, toluene, tichloroethylene, xylene.
Claims
1 . A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent and at least one pharmaceutically acceptable excipients.
2. The solid pharmaceutical composition according to claim 1, wherein the amount of amorphous dapagliflozin is between 1 0%-50.0% by weight of the total composition.
3. The solid pharmaceutical composition according to claim 2, wherein the amount of amorphous dapagliflozin is between 1.0%-40.0% or 1.0%-30.0% by weight of the total composition.
4. The solid pharmaceutical composition according to claim 1 , wherein the polar solvent is selected from the group comprising acetone, acetonitrile, ethanol, methanol, n- propanol, iso-propanol, water or mixtures thereof.
5. The solid pharmaceutical composition according to claim 1 , wherein pharmaceutically acceptable excipients are selected from the group comprising fillers, disintegrants, lubricants, glidants or mixtures thereof.
6. The solid pharmaceutical composition according to claim 5, wherein the fillers are selected from group comprising microcrystalline cellulose, anhydrous lactose, mannitol, sorbitol, sucrose, inorganic salts, calcium salts, spray-dried lactose, calcium silicate, polysaccharides, dextrose, sodium chloride, dextrates, lactitol, sugar pellet, lactose monohydrate, starch, maltodextrin, dibasic calcium phosphate, sucrose- maltodextrin mixtures, xylitol, trehalose, heavy magnesium carbonate, isomalt, or mixtures thereof.
7. The solid pharmaceutical composition according to claim 6, wherein the amount of fillers is between 10.0%-90.0% by weight of the total composition.
8. The solid pharmaceutical composition according to claim 5, wherein the disintegrants are selected from the group comprising crospovidone, povidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, polyacrylate potassium, sodium alginate, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
9. The solid pharmaceutical composition according to claim 8, wherein the amount of disintegrants is between 0.5%-20.0% by weight of the total composition.
10. The solid pharmaceutical composition according to claim 5, wherein the lubricants are selected from the group comprising magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
11. The solid pharmaceutical composition according to claim 10, wherein the amount of lubricants is between 0.05%-5.0% by weight of the total composition.
12. The solid pharmaceutical composition according to claim 5, wherein the glidants are selected from the group comprising silicon dioxide, talc, aluminium silicate, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
13. The solid pharmaceutical composition according to claim 12, wherein the amount of glidants is between 0.05%-5.0% by weight of the total composition.
14. The solid pharmaceutical composition according to any preceding claims, wherein the composition is in the form of a tablet or a capsule.
15. The solid pharmaceutical composition according to claim 14, comprising;
- Amorphous dapagliflozin isolated from polar solvent
- Microcrystalline cellulose
- Anhydrous lactose
- Crospovidone
- Magnesium stearate
- Silicon dioxide
16. The solid pharmaceutical composition according to claim 15, comprising;
- 1 .0%- 50.0% by weight of amorphous dapagliflozin isolated from polar solvent
- 10.0% - 90.0% by weight of microcrystalline cellulose
- 5.0% - 30.0% by weight of anhydrous lactose
- 0.5% - 20.0% by weight of crospovidone
- 0.05% - 5.0% by weight of magnesium stearate
- 0.05% - 5.0% by weight of silicon dioxide in the total composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2019/18102A TR201918102A1 (en) | 2019-11-20 | 2019-11-20 | A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent |
| PCT/TR2020/050999 WO2021101482A1 (en) | 2019-11-20 | 2020-10-27 | A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4061378A1 true EP4061378A1 (en) | 2022-09-28 |
| EP4061378A4 EP4061378A4 (en) | 2023-12-06 |
Family
ID=75980709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20890661.0A Withdrawn EP4061378A4 (en) | 2019-11-20 | 2020-10-27 | A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4061378A4 (en) |
| TR (1) | TR201918102A1 (en) |
| WO (1) | WO2021101482A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113648304A (en) * | 2021-09-06 | 2021-11-16 | 扬子江药业集团上海海尼药业有限公司 | Pharmaceutical composition containing dapagliflozin and preparation method and application thereof |
| WO2023175573A1 (en) * | 2022-03-17 | 2023-09-21 | Zydus Lifesciences Limited | Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor |
| WO2025144122A1 (en) * | 2023-12-27 | 2025-07-03 | Santa Farma Ilac Sanayii A.S. | Pharmaceutical composition comprising dapagliflozin base in amorphous form |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015104658A2 (en) | 2014-01-08 | 2015-07-16 | Dr. Reddy’S Laboratories Limited | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin |
| IN2014MU00626A (en) * | 2014-02-21 | 2015-09-25 | Cadila Healthcare Ltd | |
| WO2016161995A1 (en) * | 2015-04-08 | 2016-10-13 | Zentiva, K.S. | Solid forms of amorphous dapagliflozin |
-
2019
- 2019-11-20 TR TR2019/18102A patent/TR201918102A1/en unknown
-
2020
- 2020-10-27 EP EP20890661.0A patent/EP4061378A4/en not_active Withdrawn
- 2020-10-27 WO PCT/TR2020/050999 patent/WO2021101482A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021101482A1 (en) | 2021-05-27 |
| TR201918102A1 (en) | 2021-07-26 |
| EP4061378A4 (en) | 2023-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2452019T3 (en) | Bilayer tablet comprising telmisartan and amlodipine | |
| KR101840182B1 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| US6696496B2 (en) | Low water-soluble venlafaxine salts | |
| JP5231906B2 (en) | Splittable galenic form with controlled release of active ingredients | |
| EP4061378A1 (en) | A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent | |
| AU2022202500B2 (en) | Elagolix formulation | |
| EP2554159A1 (en) | Dosage forms comprising apixaban and content uniformity enhancer | |
| US20030190352A1 (en) | Compositions of venlafaxine base | |
| US6717015B2 (en) | Venlafaxine besylate | |
| EP3976014A1 (en) | A combination comprising alogliptin and metformin | |
| JP2013533881A (en) | Pharmaceutical composition containing vanoxerin | |
| SK1752001A3 (en) | Pharmaceutical compositions comprising ibuprofen and domperidone | |
| EP4079296A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
| EP4008317A1 (en) | Solid pharmaceutical formulations of amorphous dapagliflozin | |
| US5785995A (en) | Pharmaceutical tablet of amiodarone salt | |
| US8772346B2 (en) | Pharmaceutical composition | |
| JP2023008994A (en) | Method for improving leachability of apixaban | |
| EP4008315A1 (en) | A process for formulations of dapagliflozin and metformin hydrochloride | |
| US20030119882A1 (en) | Solid pharmaceutical composition containing torasemide | |
| KR101809886B1 (en) | Minimized Oral Dosage Formulation of Clarithromycin | |
| TWI730289B (en) | Composition of aminopyran derivatives | |
| EP4023217A1 (en) | Pharmaceutical capsule compositions of alogliptine | |
| EP4556001A1 (en) | A bilayer tablet composition comprising dapagliflozin and metformin | |
| WO2023129050A1 (en) | A pharmaceutical composition of empagliflozin and linagliptin processed with hot-melt extrusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220517 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230708 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20231108 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/10 20060101ALI20231102BHEP Ipc: C07D 309/10 20060101ALI20231102BHEP Ipc: A61K 31/7034 20060101ALI20231102BHEP Ipc: A61K 31/70 20060101AFI20231102BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20240529 |